Skip to main content

Publication: CO.27 international IROCAS trial

CO27 ESMO presentation by Dr Bennouna Jaafar, a medical oncologist
A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: results of the international IROCAS study
 
CO.27 IROCAS was a phase III, multicenter, open-labeled randomized trial comparing the combinations of 5-fluorouracil (5-FU), folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX) versus oxaliplatin, folinic acid, and 5-FU (mFOLFOX 6) in patients with high-risk stage III colon cancer in the adjuvant setting.
 
The recent ESMO presentation by Dr Bennouna Jaafar, a medical oncologist at Foch Hospital, Suresnes who led the study, showed that adjuvant mFOLFIRINOX triplet chemotherapy did not improve DFS compared with standard doublet mFOLFOX6. “While disappointing, this definitively answers an important question in the adjuvant setting” says Dr. Sharlene Gill, BC Cancer Medical Oncologist and CCTG GI Committee Chair. "The findings from CO.27 do not support empirical chemotherapy intensification and highlight the need for novel adjuvant strategies”. CCTG participated in the international trial led by our partners at UNICANCER.
 
“The IROCAS study is another example of the longstanding and highly productive academic partnership between UNICANCER and the Canadian Cancer Trials Group, built on mutual respect, shared scientific priorities, and a commitment to improving cancer care," says Dr Chris O'Callaghan, CCTG Senior Investigator. "Our continued collaboration reflects the value of international academic partnerships in advancing the science of gastrointestinal cancer research, and we look forward to building on this strong foundation to address important clinical questions and improve outcomes for patients in the future.”
 
Bennouna J, André T, Martin E, Cremolini C, Gill S, Asmis T, Kavan P, Mitry E, Hiret S, Mineur L, Artru P, Perret C, Bouché O, Touchefeu Y, Goldenberg B, Dupuis O, Lonardi S, Chibaudel B, Castanié H, Coutzac C, Bauguion L, Guardiola E, Benmaziane A, Barrière J, Chen E, Simmet V, Allegrini G, Marmorino F, Pezzella V, Monard L, Campion L, O’Callaghan C, Taieb J. A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: results of the international IROCAS study (ONLINE). Annals of Oncology